Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL749760 | 1.00 | CYP11B2 (0.46) | CYP11B2CYP11B1IMPDH2SLC22A12PIK3CA | |
| SCHEMBL749910 | 0.90 | CYP11B2 (0.49) | CYP11B2CYP11B1SLC22A12PIK3CAALPL | |
| SCHEMBL749701 | 0.88 | CYP11B2 (0.45) | CYP11B2CYP11B1SLC22A12PIK3CAALPL | |
| SCHEMBL3477444 | 0.85 | CYP11B2 (0.53) | CYP11B2CYP11B1SLC22A12ALPL | |
| SCHEMBL748264 | 0.85 | CYP11B2 (0.53) | CYP11B2CYP11B1SLC22A12PIK3CAALPL | |
| SCHEMBL745748 | 0.83 | CYP11B2 (0.47) | CYP11B2CYP11B1SLC22A12ALPL | |
| SCHEMBL746742 | 0.82 | CYP11B2 (0.49) | CYP11B2CYP11B1SLC22A12ALPL | |
| SCHEMBL746798 | 0.81 | CYP11B2 (0.47) | CYP11B2CYP11B1SLC22A12ALPLSGK1 | |
| SCHEMBL747261 | 0.78 | ALPL (0.54) | CYP11B2CYP11B1SLC22A12PIK3CAALPL | |
| SCHEMBL747087 | 0.77 | UCHL1 (0.48) | CYP11B2CYP11B1SLC22A12PIK3CAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |